Friday, August 24, 2018 5:14:17 AM
I think one of us doesnt fully understand the process to obtain FDA approval for a drug. I'm talking final approval like the one GWPH got for their anti epileptic seizure medicine Epidiolex.
A company must demonstrate to the FDA that the drug is effective and safe (there can be some negative side effects but they must be well documented and the damage from side effects vs damage from untreated disease is factored in, etc). The only way to prove effectiveness is the double blind clinical trials, 3 of them. These trials are super expensive so CVSI would need to sell shares and/or take on debt to get the funding.
They are a very long, timely (year +), and expensive way from getting any approval to sell this drug. As they show on their site they have yet to do the 3 clinical trials:
https://cvsciences.com/pipeline/
I could be wrong or we might be talking past each other...
A company must demonstrate to the FDA that the drug is effective and safe (there can be some negative side effects but they must be well documented and the damage from side effects vs damage from untreated disease is factored in, etc). The only way to prove effectiveness is the double blind clinical trials, 3 of them. These trials are super expensive so CVSI would need to sell shares and/or take on debt to get the funding.
They are a very long, timely (year +), and expensive way from getting any approval to sell this drug. As they show on their site they have yet to do the 3 clinical trials:
https://cvsciences.com/pipeline/
I could be wrong or we might be talking past each other...
Recent CVSI News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 08:50:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2025 08:01:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/15/2025 09:25:41 PM
